Lupin India has received the USFDA approval to market its Betamethasone Dipropionate ointment (augmented), in the American market. The corticosteroid drug is prescribed for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.
The product will be manufactured at the company’s Pithampur, Unit 3 facility. It will be produced in generic Betamethasone Dipropionate ointment USP (augmented), 0.05 per cent form.
The product is a generic version of Merck Sharp and Dohme Corp’s Diprolene ointment in the same strength.
Company Profile : Lupin Ltd